The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 327-335

  Lee, Hun Ju ^a   Daver, Naval ^a   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CD135 ANTIGEN; CRIZOTINIB; JANUS KINASE; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PLACEBO; RUXOLITINIB; STAT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3 INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; LUNG CANCER; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JANUS KINASES; LEUKEMIA, MYELOID, ACUTE; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84872554955     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2087     Document Type: Review

References (74)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937-51.
2. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37: 649-58.
3. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program 2009; 2009: 396-405.
4. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the united states by subtype and demographic characteristics, 1997- 2002. Cancer Causes Control 2008;19: 379-90.
5. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110: 4385-95.
6. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011;2: 95-107.
7. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009;31: 2349-70.
8. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 2010;13: 67-78.
9. Zhang F, Li C, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003;22: 894-905.
10. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2011;83: 1136-45.
11. Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, et al. Janus kinase 2 inhibitors in myeloproliferative disorders. Expert Opin Investig Drugs 2011;20: 41-59.
12. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101: 1535-42.
13. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88: 386-401.
14. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7: 673-83.
15. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008;19: 385-93.
16. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434: 1144-8.
17. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352: 1779-90.
18. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365: 1054-61.
19. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7: 387-97.
20. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29: 1356-63.
21. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119: 3219-25.
22. Manshouri T, Estrov Z, Quintas-Cardama A, Burger J, Zhang Y, Livun A, et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011;71: 3831-40.
23. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011;118: 6392-8.
24. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366: 799-807.
25. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366: 787-98.
26. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. Epub 2012 Jun 20.
27. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, et al. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma 2012;53: 1839-41.
28. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010;85: 403-8.
29. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355: 2452-66.
30. Kundranda MN, Tibes R, Mesa RA. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep 2012;7: 78-86.
31. Saberwal G, Horvath E, Hu L, Zhu C, Hjort E, Eklund EA. The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation. J Biol Chem 2009;284: 33242-54.
32. Konieczna I, Horvath E, Wang H, Lindsey S, Saberwal G, Bei L, et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest 2008;118: 853-67.
33. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andreasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 2011;86: 148-55.
34. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24: 1302-9.
35. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369-70.
36. Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, et al. Deletions of the transcription factor ikaros in myeloproliferative neoplasms. Leukemia 2010;24: 1290-8.
37. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009;114: 5201-5.
38. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2 mutations which are associated with adverse outcome. Blood 2012;119: 4480-5.
39. Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115: 2891-900.
40. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81: 159-66.
41. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105: 2664-70.
42. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60: 233-45.
43. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105: 973-7.
44. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106: 3370-3.
45. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106: 3377-9.
46. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006;20: 971-8.
47. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110: 375-9.
48. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107: 2098-100.
49. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2 (V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 2006;30: 1457-60.
50. Tefferi A, Lasho TL,Schwager SM, SteensmaDP, Mesa RA, Li CY, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005;131: 320-8.
51. Nguyen MH, Ho JM, Beattie BK, Barber DL. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 30-kinase/protein kinase B signaling pathway. J Biol Chem 2001;276: 32704-13.
52. Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006;108: 2770-9.
53. Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111: 4809-12.
54. Ikezoe T, Kojima S, Furihata M, Yang J, Nishioka C, Takeuchi A, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer 2011;129: 2512-21.
55. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10: 65-75.
56. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25: 1434-6.
57. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, et al. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010;5: 590-600.
58. Ikezoe T, Yang J, Nishioka C, Kojima S, Takeuchi A, Phillip Koeffler H, et al. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of Janus kinases stimulates dormant human leukemia CD34+/CD38- cells and sensitizes them to antileukemia agents. Int J Cancer 2011;128: 2317-25.
59. Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci U S A 2007;104: 18502-7.
60. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 2007;31: 91-5.
61. Olnes MJ, Poon A, Tucker Z, Young NS, Sloand EM. JAK2 inhibition with TG101348 inhibits monosomy 7 myelodysplastic syndromes (MDS) bone marrow cells in vitro: a potential targeted therapy for monosomy 7 MDS [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; Orlando, FL. Washington, DC: ASH; 2011. Abstract nr 973.
62. Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, et al. The THPO/MPL/Bcl-xL pathway is essential for survival and selfrenewal in human pre-leukemia induced by AML1-ETO. Blood 2012;120: 709-19.
63. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011;29: 591-9.
64. Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors. Leukemia 2012;26: 2233-44.
65. Ravandi F, Verstovsek S, Estrov Z, Burger JA, George S, Bivins C, et al. Significant activity of the JAK2 inhibitor, INCB018424 in patients with secondary, post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML): results of an exploratory phase II study [abstract]. In: Proceedings of the 51st ASH Annual Meeting and Exposition; 2009 Dec 5-9; New Orleans, LA. Washington, DC: ASH; 2009. Abstract nr 631.
66. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 2012;119: 4614-8.
67. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-703.
68. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005;105: 2535-42.
69. Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 2002;116: 582-6.
70. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, et al. Treatment of progression of philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the groupe francophone des myelodysplasies (GFM). Blood 2010;116: 3735-42.
71. Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27: 4760-6.
72. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3- induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010;16: 1421-8.
73. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106: 3150-9.
74. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361: 123-34.